The US FDA granted accelerated approval for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma. This approval allows Breyanzi to be used as a third-line or later therapy for follicular lymphoma, marking another significant milestone for Bristol Myers Squibb in the field of cancer treatment.
The FDA approved an innovative new treatment for patients with a form of lung cancer. It is to be used only by patients who have exhausted all other options to treat small cell lung cancer, and have a life expectancy of four to five months. https://t.co/Uw7eLS5aoz
FDA granted accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. https://t.co/zjfDDxN2lz #OCENewsBurst
Immunotherapy before and after Surgery Improves Survival in Lung Cancer Patients Results from the randomized CheckMate 77T trial showed that nivolumab significantly improved survival in operable NSCLC patients. Learn more: https://t.co/tqejzqd388 https://t.co/7mc4KjWrNJ
. @BMSnews gets another FDA approval for fast-growing CD19-directed CAR-T Breyanzi, this time as a third-line or later therapy for follicular #lymphoma. https://t.co/UkQfBEkd4A
FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma https://t.co/SHDaZ71pHr via @onclive
$BMY FDA grants accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel) a CD19-directed CAR T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). https://t.co/Cr8QGZ62WH
US FDA approves expanded use of Bristol Myers' cancer cell therapy https://t.co/n9zWNN9BqN https://t.co/n9zWNN9BqN